A Phase 1 interventional study of MSB0010841 and MSB0010841 in Psoriasis, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 1 site in Germany. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-01-19.
Sponsored by Merck KGaA, Darmstadt, Germany · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 299 studies in Psoriasis with a site in Germany — 13 open to participants now, 30 under way, 15 of them phase 3. Psoriasis · Germany.
Among the 299 studies in Psoriasis with a site in Germany, this one is the 207th largest by enrollment of the 260 interventional ones that give a count, is one of 19 that started in 2014, is one of 26 in phase 1, and was the 120th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →13 of the 299 studies in Psoriasis with a site in Germany are open now. Recruiting first, the newest first:
Takeda · Sites in Germany, United States, China and 4 more countries
Ages 4–17
Bristol-Myers Squibb · Sites in Germany, United States, Argentina and 13 more countries
Ages 12–17
UCB Biopharma SRL · Sites in Germany, United States, Canada and 10 more countries
Ages 18+
Bristol-Myers Squibb · Sites in Germany, United States, Argentina and 22 more countries
Ages 40+
LEO Pharma · Sites in Germany, United States, Canada and 2 more countries
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
299 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 34 · Phase 2 83 · Phase 3 122 · Phase 4 23
First in 2000; this study’s year is marked. 19 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 41 is below the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 196 across the 260 interventional studies, 588 across the 39 observational. Of the 264 that completed or were terminated, 160 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
274 of 299 have an industry lead sponsor. The 10 most frequent:
Merck KGaA, Darmstadt, Germany is the lead sponsor of 275 studies on the registry; none are open to participants now.
Merck KGaA, Darmstadt, Germany has 9 studies filed under Psoriasis — fewer than ten, so there is no comparison to draw.
2 of the studies in Psoriasis with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07013201LEO PharmaA 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis | 2027-06-04 |
| NCT03886246LEO PharmaEffisayil™ ON: A Study to Test Long-term Treatment With Spesolimab in People With Generalized Pustular Psoriasis Who Took Part in a Previous Study | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 299 studies in Psoriasis with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, Phase 1, randomized, double-blind, placebo-controlled trial in subjects with moderate to severe psoriasis to assess the safety, tolerability, immunogenicity, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of multiple subcutaneous ascending doses of MSB0010841 (Anti-interleukin-17A/F [Anti-IL-17A/F] Nanobody).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: MSB0010841
Drug: MSB0010841
Drug: MSB0010841
Drug: MSB0010841
Drug: Placebo
MSB0010841(Anti- IL-17A/F Nanobody) will be administered at a dose of 30 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
Also known as: Anti-IL-17A/F Nanobody, M1095
MSB0010841 will be administered at a dose of 60 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
Also known as: Anti-IL-17A/F Nanobody, M1095
MSB0010841 will be administered at a dose of 120 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
Also known as: Anti-IL-17A/F Nanobody, M1095
MSB0010841 will be administered at a dose of 240 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
Also known as: Anti-IL-17A/F Nanobody, M1095
Placebo matched to MSB0010841 will be administered as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
Number of Subjects With Treatment Emergent Adverse Events (TEAEs)
An adverse event (AE) was defined as any untoward medical occurrence which does not necessarily have a causal relationship with this the study drug. An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug or worsening of pre-existing medical condition, whether or not related to study drug. TEAEs were the AEs occurring or worsening after treatment administration.
Time frame: Baseline up to Day 85
Number of Subjects With Local Injection Site Reactions (ISRs)
The injection site was assessed by the Principal Investigator (PI) or his/her designee for local reactions such as redness, swelling, indurations or bruising, and by the subject for itching. Redness and bruising were scaled as None (no visible redness or bruising present); Mild (less than or equal to \[\<=\] 2.0 centimeters \[cm\] redness or bruising area); Moderate (greater than \[\>\] 2 to \<=5.0 cm redness or bruising area); Severe (\>5.0 cm redness or bruising area). Swelling was scaled as None (no swelling detected); Mild (palpable 'firmness' only); Moderate (\<= 4 cm swelling); Severe (\>4 cm swelling). Induration was scaled as None (no induration); Mild (able to move skin parallel to plane (sliding) and perpendicular to skin (pinching up); Moderate (able to slide skin, unable to pinch skin); Severe (unable to slide or pinch skin). Itching was scaled as No itching; Mild itching; Moderate itching and Severe itching. Subjects who reported any of the local ISRs were reported.
Time frame: Day 1, 2,8, 15, 16, 22, 29, 30, 36, 43
Amount of Pain at Injection Site Assessed By Visual Analog Scale (VAS)
Subjects were asked to assess their severity of injection site pain on a 100 millimeter (mm) VAS, where 0 = no pain and 100 = worst possible pain. Mean of amount of pain was calculated for the subjects having a value \> 0. Maximum values per subjects (over injection site areas) are used for counting the amount of pain at injection site. Maximum pain scores recorded among all participants analysed in each arm are reported for each time point.
Time frame: Day 1, 2, 8, 15, 16, 22, 29, 30, 36, 43
Percentage of Subjects With Anti-MSB0010841 Binding Antibodies (Anti-Drug Antibodies [ADA])
Data were presented for MSB0010841 combined group and placebo.
Time frame: Baseline up to Day 85
Levels of Anti-MSB0010841 Antibody Titers
Time frame: Day 8, 15 (pre-dose), 22, 29 (pre-dose), 36, 43, 63 and 85
Levels of Pre-existing Anti-MSB0010841 Antibody Titers
Time frame: Pre-dose on Day 1
MSB0010841 Serum Concentration Over Time After First Dose
Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1)
MSB0010841 Serum Concentration Over Time After Second Dose
Time frame: 0 hours (pre-dose), 24, 72, 96, 168, 336 hours post-second dose (Day 15)
MSB0010841 Serum Concentration Over Time After Third Dose
Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) Post First Dose of MSB0010841
Area under the serum concentration-time curve (AUC) from time zero to the last sampling time point at which the concentration is at or above lower limit of quantification (LLOQ).
Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1)
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) Post Third Dose of MSB0010841
Area under the serum concentration-time curve (AUC) from time zero to the last sampling time point at which the concentration is at or above LLOQ.
Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)
Area Under the Concentration-Time Curve From Time Zero up to Time Tau (AUCtau) Post First Dose of MSB0010841
Area under the concentration-time curve from time zero up to time Tau, where Tau is the dosing interval (336 hours).
Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1)
Area Under the Concentration-Time Curve From Time Zero up to Time Tau (AUCtau) Post Third Dose of MSB0010841
Area under the concentration-time curve from time zero up to time Tau, where Tau is the dosing interval (336 hours).
Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-third dose (Day 29)
Area Under the Concentration-time Curve From Time Zero to Infinity (AUC 0-inf) Post Third Dose of MSB0010841
Area under the serum concentration-time curve from time zero to infinity (AUC0-inf). AUC0-infcalculated as AUC0-t + AUCextra. AUCextra represents the extrapolated part of AUC0-inf calculated by Clast calc/λz, where Clast calc is the calculated concentration at the last sampling time point at which the measured concentration is at or above LLOQ and λz is the terminal rate constant determined from the terminal slope of the log transformed concentration curve using linear regression on terminal data points of the curve.
Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)
Observed Serum Concentration Immediately Before First Dose (Cpre) of MSB0010841
The observed serum concentration immediately before the first dose.
Time frame: Pre-dose (0 hours) on Day 1
Observed Serum Concentration Immediately Before Third Dose (Cpre) of MSB0010841
The observed serum concentration immediately before the third dose.
Time frame: Pre-dose (0 hours) on Day 29
Minimum Concentration Observed (Cmin) During First Dosing Interval of MSB0010841
The observed minimum serum concentration determined directly from the serum concentration-time profile of each subject.
Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1)
Minimum Concentration Observed (Cmin) During Third Dosing Interval of MSB0010841
The observed minimum serum concentration determined directly from the serum concentration-time profile of each subject.
Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)
Maximum Concentration Observed (Cmax) Post First Dose of MSB0010841
Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1)
Maximum Concentration Observed (Cmax) Post Third Dose of MSB0010841
Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)
Average Concentration (Cav) Post First Dose of MSB0010841
Cav was calculated by AUCtau/tau. Where tau is the dosing interval (336 hours).
Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1)
Average Concentration (Cav) Post Third Dose of MSB0010841
Cav was calculated by AUCtau/tau. Where tau is the dosing interval (336 hours).
Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)
Mean Residence Time (MRT0-t) Post First Dose of MSB0010841
MRT is the average time at which the number of absorbed molecules reside in the body, after single-dose administration, and calculated as AUMC(0-t)/AUC(0-t) where AUMC(0-t) is area under the plasma concentration-time first moment curve from time zero to time t (336 hours) and AUC(0-t) is the area under the plasma concentration-time curve from time zero to tome t (336 hours).
Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1)
Mean Residence Time (MRT0-t) Post Third Dose of MSB0010841
MRT is the average time at which the number of absorbed molecules reside in the body, after single-dose administration, and calculated as AUMC(0-t)/AUC(0-t) where AUMC(0-t) is area under the plasma concentration-time first moment curve from time zero to time t (336 hours) and AUC(0-t) is the area under the plasma concentration-time curve from time zero to tome t (336 hours).
Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-third dose (Day 29)
Mean Residence Time of Drug in the Body From Time Zero Extrapolated to Infinity (MRT(0-inf) Post Third Dose of MSB0010841
Mean residence time of drug in the body from time zero extrapolated to infinity, based on the last predicted concentration at tlast.
Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)
Time to Reach Maximum Observed Concentration (Tmax) Post First Dose of MSB0010841
Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1)
Time to Maximum Observed Concentration (Tmax) Post Second Dose of MSB0010841
Time frame: 0 hours (pre-dose), 24, 72, 96, 168, 336 hours post-second dose (Day 15)
Time to Reach Maximum Observed Concentration (Tmax) Post Third Dose of MSB0010841
Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)
Apparent Terminal Half-life (t1/2) Post Third Dose of MSB0010841
Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life is calculated by dividing the natural logarithm to the base e (Log e) multiplied by (\*) 2/ λz, where 'λz' is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)
Terminal Rate Constant (λz) Post Third Dose of MSB0010841
Terminal rate constant was determined from the terminal slope of the logtransformed concentration curve using linear regression on terminal data points of the curve
Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)
Apparent Clearance (CL/f) Post Third Dose of MSB0010841
Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent clearance after oral dose (CL/f) is influenced by the fraction absorbed.
Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)
Apparent Volume of Distribution During Terminal Phase (Vz/f) Post Third Dose of MSB0010841
Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution during the terminal phase, calculated as Vz = Dose/AUC0-inf multiplied by elimination rate constant \[λz\]) following first dose and Dose/(AUCtau multiplied by λz) after third dose.
Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)
Percentage Peak-Trough Fluctuation (PTF) Post First Dose of MSB0010841
The peak trough fluctuation within one dosing interval, calculated as PTF (%) = (\[Cmax - Cmin\]/Cav ) multiplied by 100
Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1)
Percentage Peak-Trough Fluctuation (PTF) Post Third Dose of MSB0010841
The peak trough fluctuation within one dosing interval, calculated as PTF (%) = (\[Cmax - Cmin\]/Cav ) multiplied by 100
Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)
Accumulation Ratio of Cmax (Racc (Cmax))
Accumulation ratio for Cmax was calculated as Cmax, after third dose / Cmax, after first dose.
Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1) and 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)
Accumulation Ratio of AUC (Racc(AUC))
Accumulation ratio for AUC, calculated as area under the serum concentration-time curve within one complete dosing interval at third dose divided by area under the serum concentration-time curve within one complete dosing interval at first dose.
Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1) and 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)
Maximum Observed Concentration (Cmax) Post Second Dose of MSB0010841
Time frame: 0 hours (pre-dose), 24, 72, 96, 168, 336 hours post-second dose (Day 15)
Observed Serum Concentration Immediately Before Second Dose (Cpre) of MSB0010841
The observed serum concentration immediately before second dose.
Time frame: Pre-dose (0 hours) on Day 15
Percentage of Subjects With 50% or 75% Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score
PASI: a physician assessed index that measured psoriasis severity and evaluated erythema, infiltration, and desquamation (scaling) on different body areas including the head, upper extremities, the trunk, and lower extremities. T Erythema, infiltration, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. These values for each anatomic region are summed to yield the PASI score. PASI score ranged from 0 to 72, with higher scores reflecting greater disease severity. PASI 50% or 75% was defined as the percentage of participants who achieved \>=50 or 75% improvement in PASI score from Baseline.
Time frame: Baseline up to Day 85
Mean Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Day 43
PASI: a physician assessed index that measured psoriasis severity and evaluated erythema, infiltration, and desquamation (scaling) on different body areas including the head, upper extremities, the trunk, and lower extremities. T Erythema, infiltration, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. These values for each anatomic region are summed to yield the PASI score. PASI score ranged from 0 to 72, with higher scores reflecting greater disease severity. PASI 50% or 75% was defined as the percentage of subjects who achieved \>=50 or 75% improvement in PASI score from Baseline.
Time frame: Baseline, Day 43
Percentage of Subjects With Static Physician's Global Assessment (sPGA) Score of Minimal or Clear and With at Least 2 Level Reduction From Baseline
The static Physician's Global Assessment (sPGA) scale rated the investigator's overall clinical assessment of a subjects plaque thickness, erythema, and scaling on a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (majority of plaques have severe thickness, erythema, and scale). To assign a sPGA score, the investigator examined all psoriatic lesions and assigned a severity score ranging from 0 to 5 for thickness, erythema, and scaling. Scores for thickness, erythema, and scaling are summed and the mean of these 3 scores equals the overall sPGA score. Overall sPGA score ranged from 0 to 5, where lower scores indicate clinical improvement. Percentage of subjects who achieved a sPGA rating of 0 (clear) or 1 (minimal) and had at Least 2 level reduction from Baseline score were reported.
Time frame: Day 8, 15, 22, 29, 36, 43, 50, 85
Mean Percent Change From Baseline in the Body Surface Area (BSA) Affected by Psoriasis at Day 8, 15, 22, 29, 36, 43, 50 and 85
The BSA is the physician's evaluation for the extent of disease. The entire body area is divided into 4 districts: head, upper limbs, trunk and lower limbs to which corresponds the 10%, 20%, 30% and 40% of the entire body surface respectively. The investigator assesses the percentage of the subjects' body surface area affected by psoriasis in each district. The final affected BSA value is the sum of the percentage of each district.
Time frame: Baseline, Day 8, 15, 22, 29, 36, 43, 50 and 85
Percentage of Subjects With Exacerbation of Psoriasis
Psoriasis exacerbation was defined as either a worsening of 25% over the baseline value of the PASI score (PASI score at any visit \>=125% of baseline PASI).
Time frame: Baseline up to Day 85
| Milestone | MSB0010841 30 mg | MSB0010841 60 mg | MSB0010841 120 mg | MSB0010841 240 mg | Placebo |
|---|---|---|---|---|---|
| Started | 8 | 8 | 8 | 9 | 8 |
| Completed | 8 | 8 | 7 | 7 | 8 |
| Not completed | 0 | 0 | 1 | 2 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 | 1 | 0 |
| Withdrew: Quantiferon positivity | 0 | 0 | 0 | 1 | 0 |
An adverse event (AE) was defined as any untoward medical occurrence which does not necessarily have a causal relationship with this the study drug. An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug or worsening of pre-existing medical condition, whether or not related to study drug. TEAEs were the AEs occurring or worsening after treatment administration.
| subjects | MSB0010841 30 mg | MSB0010841 60 mg | MSB0010841 120 mg | MSB0010841 240 mg | Placebo |
|---|---|---|---|---|---|
| Number of Subjects With Treatment Emergent Adverse Events (TEAEs) | 6 | 5 | 5 | 6 | 6 |
The injection site was assessed by the Principal Investigator (PI) or his/her designee for local reactions such as redness, swelling, indurations or bruising, and by the subject for itching. Redness and bruising were scaled as None (no visible redness or bruising present); Mild (less than or equal to \[\<=\] 2.0 centimeters \[cm\] redness or bruising area); Moderate (greater than \[\>\] 2 to \<=5.0 cm redness or bruising area); Severe (\>5.0 cm redness or bruising area). Swelling was scaled as None (no swelling detected); Mild (palpable 'firmness' only); Moderate (\<= 4 cm swelling); Severe (\>4 cm swelling). Induration was scaled as None (no induration); Mild (able to move skin parallel to plane (sliding) and perpendicular to skin (pinching up); Moderate (able to slide skin, unable to pinch skin); Severe (unable to slide or pinch skin). Itching was scaled as No itching; Mild itching; Moderate itching and Severe itching. Subjects who reported any of the local ISRs were reported.
| subjects | MSB0010841 30 mg | MSB0010841 60 mg | MSB0010841 120 mg | MSB0010841 240 mg | Placebo |
|---|---|---|---|---|---|
| Day 1 Bruising: none (n=8,8,8,9,8) | 8 | 8 | 8 | 9 | 8 |
| Day 1 Indurations: none (n=8,8,8,9,8) | 8 | 8 | 7 | 9 | 8 |
| Day 1 Indurations: mild (n=8,8,8,9,8) | 0 | 0 | 1 | 0 | 0 |
| Day 1 Itching: none (n=8,8,8,9,8) | 8 | 8 | 8 | 8 | 9 |
| Day 1 Itching: mild (n=8,8,8,9,8) | 0 | 0 | 0 | 1 | 0 |
| Day 1 Redness: none (n=8,8,8,9,8) | 8 | 7 | 8 | 8 | 6 |
| Day 1 Redness: mild (n=8,8,8,9,8) | 0 | 1 | 0 | 1 | 2 |
| Day 1 Swelling: none (n=8,8,8,9,8) | 8 | 7 | 8 | 9 | 8 |
| Day 1 Swelling: mild (n=8,8,8,9,8) | 0 | 1 | 0 | 0 | 0 |
| Day 2 Bruising: none (n=8,8,8,9,8) | 5 | 8 | 8 | 9 | 8 |
| Day 2 Bruising: mild (n=8,8,8,9,8) | 3 | 0 | 0 | 0 | 0 |
| Day 2 Indurations: none (n=8,8,8,9,8) | 8 | 8 | 8 | 9 | 8 |
| Day 2 Itching: none (n=8,8,8,9,8) | 8 | 8 | 8 | 9 | 8 |
| Day 2 Redness: none (n=8,8,8,9,8) | 8 | 8 | 8 | 9 | 8 |
| Day 2 Swelling: none (n=8,8,8,9,8) | 8 | 8 | 8 | 9 | 8 |
| Day 8 Bruising: none (n=8,8,8,8,8) | 8 | 8 | 8 | 8 | 8 |
| Day 8 Indurations: none (n=8,8,8,8,8) | 8 | 8 | 8 | 8 | 8 |
| Day 8 Itching: none (n=8,8,8,8,8) | 8 | 8 | 8 | 8 | 8 |
| Day 8 Redness: none (n=8,8,8,8,8) | 7 | 8 | 8 | 8 | 8 |
| Day 8 Redness: mild (n=8,8,8,8,8) | 1 | 0 | 0 | 0 | 0 |
| Day 8 Swelling: none (n=8,8,8,8,8) | 8 | 8 | 8 | 8 | 8 |
| Day 15 Bruising: none (n=8,8,8,8,8) | 8 | 8 | 8 | 8 | 8 |
| Day 15 Indurations: none (n=8,8,8,8,8) | 8 | 8 | 8 | 8 | 8 |
| Day 15 Itching: none (n=8,8,8,8,8) | 8 | 8 | 8 | 8 | 8 |
| Day 15 Redness: none (n=8,8,8,8,8) | 8 | 7 | 7 | 8 | 8 |
| Day 15 Redness: mild (n=8,8,8,8,8) | 0 | 1 | 0 | 0 | 0 |
| Day 15 Redness: moderate (n=8,8,8,8,8) | 0 | 0 | 1 | 0 | 0 |
| Day 15 Swelling: none (n=8,8,8,8,8) | 8 | 8 | 8 | 8 | 8 |
| Day 16 Bruising: none (n=8,8,8,8,8) | 8 | 7 | 8 | 7 | 8 |
| Day 16 Bruising: mild (n=8,8,8,8,8) | 0 | 1 | 0 | 1 | 0 |
| Day 16 Indurations: none (n=8,8,8,8,8) | 8 | 8 | 8 | 8 | 8 |
| Day 16 Itching: none (n=8,8,8,8,8) | 8 | 8 | 8 | 8 | 8 |
| Day 16 Redness: none (n=8,8,8,8,8) | 7 | 8 | 8 | 8 | 8 |
| Day 16 Redness: mild (n=8,8,8,8,8) | 1 | 0 | 0 | 0 | 0 |
| Day 16 Swelling: none (n=8,8,8,8,8) | 8 | 8 | 7 | 8 | 8 |
| Day 16 Swelling: mild (n=8,8,8,8,8) | 0 | 0 | 1 | 0 | 0 |
| Day 22 Bruising: none (n=8,8,8,8,8) | 8 | 8 | 8 | 7 | 8 |
| Day 22 Bruising: mild (n=8,8,8,8,8) | 0 | 0 | 0 | 1 | 0 |
| Day 22 Indurations: none (n=8,8,8,8,8) | 8 | 8 | 7 | 8 | 8 |
| Day 22 Indurations: severe (n=8,8,8,8,8) | 0 | 0 | 1 | 0 | 0 |
| Day 22 Itching: none (n=8,8,8,8,8) | 7 | 8 | 8 | 8 | 8 |
| Day 22 Itching: mild (n=8,8,8,8,8) | 1 | 0 | 0 | 0 | 0 |
| Day 22 Redness: none (n=8,8,8,8,8) | 8 | 8 | 7 | 8 | 8 |
| Day 22 Redness: severe (n=8,8,8,8,8) | 0 | 0 | 1 | 0 | 0 |
| Day 22 Swelling: none (n=8,8,8,8,8) | 8 | 8 | 7 | 8 | 8 |
| Day 22 Swelling: severe (n=8,8,8,8,8) | 0 | 0 | 1 | 0 | 0 |
| Day 29 Bruising: none (n=8,8,8,7,8) | 8 | 8 | 8 | 7 | 8 |
| Day 29 Indurations: none (n=8,8,7,7,8) | 8 | 8 | 7 | 7 | 8 |
| Day 29 Itching: none (n=8,8,8,7,8) | 8 | 8 | 8 | 7 | 8 |
| Day 29 Redness: none (n=8,8,8,8,8) | 8 | 8 | 6 | 5 | 8 |
| Day 29 Redness: mild (n=8,8,8,8,8) | 0 | 0 | 2 | 2 | 0 |
| Day 29 Redness: moderate (n=8,8,8,8,8) | 0 | 0 | 0 | 1 | 0 |
| Day 29 Swelling: none (n=8,8,8,7,8) | 8 | 8 | 7 | 7 | 8 |
| Day 29 Swelling: mild (n=8,8,8,7,8) | 0 | 0 | 1 | 0 | 0 |
| Day 30 Bruising: none (n=8,8,8,7,8) | 8 | 8 | 7 | 6 | 8 |
| Day 30 Bruising: mild (n=8,8,8,7,8) | 0 | 0 | 1 | 1 | 0 |
| Day 30 Indurations: none (n=8,8,7,7,8) | 8 | 8 | 7 | 7 | 8 |
| Day 30 Itching: none (n=8,8,7,7,8) | 8 | 8 | 0 | 0 | 8 |
| Day 30 Redness: none (n==8,8,7,7,8) | 8 | 8 | 7 | 6 | 8 |
| Day 30 Redness: moderate (n=8,8,7,7,8) | 0 | 0 | 0 | 1 | 0 |
| Day 30 Swelling: none (n=8,8,7,7,8) | 8 | 8 | 7 | 7 | 8 |
| Day 36 Bruising: none (n=7,8,7,7,8) | 7 | 8 | 7 | 6 | 8 |
| Day 36 Bruising: mild (n=7,8,7,7,8) | 0 | 0 | 0 | 1 | 0 |
| Day 36 Indurations: none (n=8,8,7,7,7) | 8 | 8 | 7 | 7 | 7 |
| Day 36 Itching: none (n=7,8,7,6,8) | 7 | 8 | 7 | 6 | 8 |
| Day 43 Bruising: none (n=8,8,8,8,8) | 8 | 8 | 8 | 8 | 8 |
| Day 43 Indurations: none (n=8,8,8,8,8) | 8 | 8 | 8 | 8 | 8 |
| Day 43 Itching: none (8,8,8,8,8) | 8 | 8 | 8 | 8 | 8 |
| Day 43 Redness: none (n=8,8,8,8,8) | 8 | 8 | 7 | 8 | 8 |
| Day 43 Redness: moderate (n=8,8,8,8,8) | 0 | 0 | 1 | 0 | 0 |
| Day 43 Swelling: none (n=8,8,8,8,8) | 8 | 8 | 8 | 8 | 8 |
Subjects were asked to assess their severity of injection site pain on a 100 millimeter (mm) VAS, where 0 = no pain and 100 = worst possible pain. Mean of amount of pain was calculated for the subjects having a value \> 0. Maximum values per subjects (over injection site areas) are used for counting the amount of pain at injection site. Maximum pain scores recorded among all participants analysed in each arm are reported for each time point.
| mm | MSB0010841 30 mg | MSB0010841 60 mg | MSB0010841 120 mg | MSB0010841 240 mg | Placebo |
|---|---|---|---|---|---|
| Day 1 (n=3,2,3,2,0) | 7 | 4 | 7 | 4 | NA |
| Day 2 (n=1,1,1,1,0) | 1 | 1 | 1 | 1 | NA |
| Day 8 (n=1,1,0,0,0) | 1 | 1 | NA | NA | NA |
| Day 15 (n=2,1,3,0,0) | 5 | 3 | 7 | NA | NA |
| Day 16 (n=0,0,0,0,2) | NA | NA | NA | NA | 2 |
| Day 22 (1,0,1,0,0) | 11 | NA | 1 | NA | NA |
| Day 29 (n=1,1,1,0,0) | 3 | 2 | 2 | NA | NA |
| Day 30 (1,0,1,1,0) | 2 | NA | 1 | 1 | NA |
| Day 36 (n=0,0,0,0,0) | NA | NA | NA | NA | NA |
| Day 43 (n=0,0,0,0,0) | NA | NA | NA | NA | NA |
Data were presented for MSB0010841 combined group and placebo.
| percentage of subjects | MSB0010841 Combined | Placebo |
|---|---|---|
| Percentage of Subjects With Anti-MSB0010841 Binding Antibodies (Anti-Drug Antibodies [ADA]) | 30.3 | 37.5 |
| log10titer | ADA Positive Subjects |
|---|---|
| Day 8 Subject 1: Placebo | 3.68 |
| Day 8 Subject 2: Placebo | 3.68 |
| Day 8 Subject 3: Placebo | 3.68 |
| Day 8 Subject 4: MSB0010841 30 mg | 3.68 |
| Day 8 Subject 5: MSB0010841 30 mg | 0 |
| Day 8 Subject 6: MSB0010841 30 mg | 2.28 |
| Day 8 Subject 7: MSB0010841 60 mg | 0 |
| Day 8 Subject 8: MSB0010841 120 mg | 3.68 |
| Day 8 Subject 9: MSB0010841 120 mg | 4.38 |
| Day 8 Subject 10: MSB0010841 120 mg | 3.68 |
| Day 8 Subject 11: MSB0010841 120 mg | 4.38 |
| Day 8 Subject 12: MSB0010841 120 mg | 2.98 |
| Day 8 Subject 13: MSB0010841 240 mg | 2.98 |
| Day 15 (pre-dose) Subject 1: Placebo | 3.68 |
| Day 15 (pre-dose) Subject 2: Placebo | 3.68 |
| Day 15 (pre-dose) Subject 3: Placebo | 3.68 |
| Day 15 (pre-dose) Subject 4: MSB0010841 30 mg | 3.68 |
| Day 15 (pre-dose) Subject 5: MSB0010841 30 mg | 0 |
| Day 15 (pre-dose) Subject 6: MSB0010841 30 mg | 2.28 |
| Day 15 (pre-dose) Subject 7: MSB0010841 60 mg | 2.98 |
| Day 15 (pre-dose) Subject 8: MSB0010841 120 mg | 5.78 |
| Day 15 (pre-dose) Subject 9: MSB0010841 120 mg | 4.38 |
| Day 15 (pre-dose) Subject 10: MSB0010841 120 mg | 3.68 |
| Day 15 (pre-dose) Subject 11: MSB0010841 120 mg | 4.38 |
| Day 15 (pre-dose) Subject 12: MSB0010841 120 mg | 2.98 |
| Day 15 (pre-dose) Subject 13: MSB0010841 240 mg | 2.98 |
| Day 22 Subject 1: Placebo | 3.68 |
| Day 22 Subject 2: Placebo | 3.68 |
| Day 22 Subject 3: Placebo | 3.68 |
| Day 22 Subject 4: MSB0010841 30 mg | 3.68 |
| Day 22 Subject 5: MSB0010841 30 mg | 2.98 |
| Day 22 Subject 6: MSB0010841 30 mg | 2.98 |
| Day 22 Subject 7: MSB0010841 60 mg | 2.28 |
| Day 22 Subject 8: MSB0010841 120 mg | 2.98 |
| Day 22 Subject 9: MSB0010841 120 mg | 4.38 |
| Day 22 Subject 10: MSB0010841 120 mg | 3.68 |
| Day 22 Subject 11: MSB0010841 120 mg | 4.38 |
| Day 22 Subject 12: MSB0010841 120 mg | 2.98 |
| Day 22 Subject 13: MSB0010841 240 mg | 2.98 |
| Day 29 (pre-dose) Subject 1: Placebo | 3.68 |
| Day 29 (pre-dose) Subject 2: Placebo | 3.68 |
| Day 29 (pre-dose) Subject 3: Placebo | 3.68 |
| Day 29 (pre-dose) Subject 4: MSB0010841 30 mg | 2.98 |
| Day 29 (pre-dose) Subject 5: MSB0010841 30 mg | 0 |
| Day 29 (pre-dose) Subject 6: MSB0010841 30 mg | 2.98 |
| Day 29 (pre-dose) Subject 7: MSB0010841 60 mg | 2.28 |
| Day 29 (pre-dose) Subject 8: MSB0010841 120 mg | 3.68 |
| Day 29 (pre-dose) Subject 9: MSB0010841 120 mg | 3.68 |
| Day 29 (pre-dose) Subject 10: MSB0010841 120 mg | 3.68 |
| Day 29 (pre-dose) Subject 11: MSB0010841 120 mg | 4.38 |
| Day 29 (pre-dose) Subject 12: MSB0010841 120 mg | 2.98 |
| Day 29 (pre-dose) Subject 13: MSB0010841 240 mg | 2.98 |
| Day 36 Subject 1: Placebo | NA |
| Day 36 Subject 2: Placebo | 3.68 |
| Day 36 Subject 3: Placebo | 3.68 |
| Day 36 Subject 4: MSB0010841 30 mg | 2.98 |
| Day 36 Subject 5: MSB0010841 30 mg | 0 |
| Day 36 Subject 6: MSB0010841 30 mg | 2.98 |
| Day 36 Subject 7: MSB0010841 60 mg | 2.98 |
| Day 36 Subject 8: MSB0010841 120 mg | NA |
| Day 36 Subject 9: MSB0010841 120 mg | 3.68 |
| Day 36 Subject 10: MSB0010841 120 mg | 4.38 |
| Day 36 Subject 11: MSB0010841 120 mg | 4.38 |
| Day 36 Subject 12: MSB0010841 120 mg | 3.68 |
| Day 36 Subject 13: MSB0010841 240 mg | 2.98 |
| Day 43 Subject 1: Placebo | 2.98 |
| Day 43 Subject 2: Placebo | 3.68 |
| Day 43 Subject 3: Placebo | 3.68 |
| Day 43 Subject 4: MSB0010841 30 mg | 2.98 |
| Day 43 Subject 5: MSB0010841 30 mg | 0 |
| Day 43 Subject 6: MSB0010841 30 mg | 2.98 |
| Day 43 Subject 7: MSB0010841 60 mg | 2.28 |
| Day 43 Subject 8: MSB0010841 120 mg | 4.38 |
| Day 43 Subject 9: MSB0010841 120 mg | 3.68 |
| Day 43 Subject 10: MSB0010841 120 mg | 4.38 |
| Day 43 Subject 11: MSB0010841 120 mg | 3.68 |
| Day 43 Subject 12: MSB0010841 120 mg | 2.98 |
| Day 43 Subject 13: MSB0010841 240 mg | 2.98 |
| Day 63 Subject 1: Placebo | 3.68 |
| Day 63 Subject 2: Placebo | 3.68 |
| Day 63 Subject 3: Placebo | 3.68 |
| Day 63 Subject 4: MSB0010841 30 mg | 4.38 |
| Day 63 Subject 5: MSB0010841 30 mg | 0 |
| Day 63 Subject 6: MSB0010841 30 mg | 2.98 |
| Day 63 Subject 7: MSB0010841 60 mg | 2.28 |
| Day 63 Subject 8: MSB0010841 120 mg | 2.98 |
| Day 63 Subject 9: MSB0010841 120 mg | 3.68 |
| Day 63 Subject 10: MSB0010841 120 mg | 3.68 |
| Day 63 Subject 11: MSB0010841 120 mg | 3.68 |
| Day 63 Subject 12: MSB0010841 120 mg | 3.68 |
| Day 63 Subject 13: MSB0010841 240 mg | 2.98 |
| Day 85 Subject 1: Placebo | 3.68 |
| Day 85 Subject 2: Placebo | 3.68 |
| Day 85 Subject 3: Placebo | 3.68 |
| Day 85 Subject 4: MSB0010841 30 mg | 3.68 |
| Day 85 Subject 5: MSB0010841 30 mg | 0 |
| Day 85 Subject 6: MSB0010841 30 mg | 2.28 |
| Day 85 Subject 7: MSB0010841 60 mg | 2.28 |
| Day 85 Subject 8: MSB0010841 120 mg | 2.98 |
| Day 85 Subject 9: MSB0010841 120 mg | 3.68 |
| Day 85 Subject 10: MSB0010841 120 mg | 3.68 |
| Day 85 Subject 11: MSB0010841 120 mg | 2.98 |
| Day 85 Subject 12: MSB0010841 120 mg | 3.68 |
| Day 85 Subject 13: MSB0010841 240 mg | 2.98 |
| log10titer | ADA Positive Subjects |
|---|---|
| Subject 1: Placebo | 2.98 |
| Subject 2: Placebo | 3.68 |
| Subject 3: Placebo | 3.68 |
| Subject 4: MSB0010841 30 mg | 2.98 |
| Subject 5: MSB0010841 30 mg | 0 |
| Subject 6: MSB0010841 30 mg | 0 |
| Subject 7: MSB0010841 60 mg | 0 |
| Subject 8: MSB0010841 120 mg | 2.98 |
| Subject 9: MSB0010841 120 mg | 5.08 |
| Subject 10: MSB0010841 120 mg | 3.68 |
| Subject 11: MSB0010841 120 mg | 3.68 |
| Subject 12: MSB0010841 120 mg | 2.98 |
| Subject 13: MSB0010841 240 mg | 0 |
| nanogram/milliliter (ng/mL) | MSB0010841 30 mg | MSB0010841 60 mg | MSB0010841 120 mg | MSB0010841 240 mg |
|---|---|---|---|---|
| 0 hour (n=8,8,8,9) | 12.6 ± 35.71 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| 6 hour (n=8,8,8,9) | 907.5 ± 523.16 | 2097.1 ± 1391.43 | 2315.5 ± 787.02 | 4858.8 ± 2326.35 |
| 12 hour (n=8,8,8,9) | 1793.3 ± 761.23 | 3339.6 ± 1671.29 | 4983.1 ± 1501.41 | 9780.3 ± 4698.97 |
| 24 hour (n=8,8,8,9) | 2788.4 ± 895.89 | 5047.8 ± 1600.25 | 9131.3 ± 2838.02 | 15357.6 ± 5295.18 |
| 32 hour (n=8,8,8,9) | 3037.3 ± 820.76 | 6028.1 ± 2269.66 | 11372.4 ± 3499.37 | 17135.2 ± 6032.66 |
| 72 hour (n=8,8,7,8) | 3190.4 ± 810.18 | 6492.9 ± 1472.29 | 11284.1 ± 2562.84 | 20536.6 ± 6716.38 |
| 96 hour (n=8,8,8,8) | 3155.8 ± 879.56 | 6423.8 ± 1824.46 | 11790.0 ± 3319.36 | 18732.9 ± 4670.66 |
| 168 hour (n=8,8,8,8) | 2665.5 ± 605.89 | 5179.5 ± 1126.74 | 10318.6 ± 2837.81 | 17761.9 ± 3072.48 |
| 336 hour (n=8,8,8,8) | 1704.3 ± 429.78 | 3951.0 ± 1353.92 | 6768.4 ± 2846.24 | 11605.8 ± 2065.58 |
| ng/mL | MSB0010841 30 mg | MSB0010841 60 mg | MSB0010841 120 mg | MSB0010841 240 mg |
|---|---|---|---|---|
| 0 hour | 1704.3 ± 429.78 | 3951.0 ± 1353.92 | 6768.4 ± 2846.24 | 11605.8 ± 2065.58 |
| 24 hour | 3808.0 ± 980.68 | 7268.9 ± 3771.98 | 15120.6 ± 3393.84 | 27664.8 ± 9231.41 |
| 72 hour | 4309.0 ± 1265.45 | 9095.5 ± 2115.16 | 17454.4 ± 4152.32 | 29902.4 ± 7523.13 |
| 96 hour | 4020.5 ± 923.65 | 8514.4 ± 1849.44 | 17081.4 ± 5056.17 | 29223.5 ± 8336.26 |
| 168 hour | 3517.8 ± 877.96 | 7180.4 ± 1705.24 | 14806.6 ± 5632.99 | 22972.5 ± 11219.87 |
| 336 hour | 2306.5 ± 588.50 | 4492.9 ± 1398.63 | 10468.9 ± 4376.75 | 16454.5 ± 4548.85 |
| ng/mL | MSB0010841 30 mg | MSB0010841 60 mg | MSB0010841 120 mg | MSB0010841 240 mg |
|---|---|---|---|---|
| 0 hour | 2306.5 ± 588.50 | 4492.9 ± 1398.63 | 10417.7 ± 4724.84 | 16173.6 ± 4837.78 |
| 6 hour | 3483.9 ± 1566.88 | 6200.1 ± 1391.38 | 12725.0 ± 5573.11 | 20452.3 ± 6683.19 |
| 12 hour | 3557.9 ± 1004.43 | 8615.5 ± 3093.46 | 13361.0 ± 5959.26 | 26051.4 ± 8770.65 |
| 24 hour | 4533.3 ± 1178.14 | 9969.9 ± 2494.60 | 17523.1 ± 6140.31 | 33651.7 ± 11590.56 |
| 32 hour | 4934.5 ± 1256.47 | 10762.5 ± 2377.88 | 18634.9 ± 5713.14 | 38278.4 ± 13391.40 |
| 72 hour | 4936.0 ± 1387.50 | 10345.6 ± 4586.24 | 19813.1 ± 6381.27 | 37166.4 ± 10103.58 |
| 96 hour | 4994.9 ± 1448.53 | 9047.6 ± 2760.25 | 18260.1 ± 6602.90 | 33909.3 ± 10219.54 |
| 168 hour | 4368.1 ± 1201.56 | 7715.4 ± 3019.93 | 15585.3 ± 5625.65 | 31375.9 ± 6826.50 |
| 336 hour | 2680.5 ± 859.35 | 5602.1 ± 3057.34 | 12257.6 ± 7468.85 | 20011.9 ± 6248.98 |
| 504 hour | 1802.0 ± 505.42 | 3109.1 ± 1519.66 | 8610.6 ± 5991.68 | 12472.4 ± 4176.00 |
| 816 hour | 933.1 ± 376.76 | 1378.1 ± 834.66 | 4309.3 ± 4044.88 | 5064.6 ± 2070.93 |
| 1056 hour | 464.5 ± 257.13 | 658.5 ± 391.39 | 2599.7 ± 2937.08 | 2475.9 ± 1391.08 |
| 1344 hour | 244.8 ± 162.24 | 326.3 ± 230.87 | 1611.3 ± 2199.92 | 1345.7 ± 879.15 |
Area under the serum concentration-time curve (AUC) from time zero to the last sampling time point at which the concentration is at or above lower limit of quantification (LLOQ).
| day*microgram per milliliter (day*mcg/mL | MSB0010841 30 mg | MSB0010841 60 mg | MSB0010841 120 mg | MSB0010841 240 mg |
|---|---|---|---|---|
| Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) Post First Dose of MSB0010841 | 33.6 ± 28.0 | 69.3 ± 18.9 | 126.3 ± 28.5 | 216.5 ± 23.4 |
Area under the serum concentration-time curve (AUC) from time zero to the last sampling time point at which the concentration is at or above LLOQ.
| day*mcg/mL | MSB0010841 30 mg | MSB0010841 60 mg | MSB0010841 120 mg | MSB0010841 240 mg |
|---|---|---|---|---|
| Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) Post Third Dose of MSB0010841 | 93.7 ± 41.4 | 170.3 ± 39.5 | 371.7 ± 62.0 | 663.4 ± 31.1 |
Area under the concentration-time curve from time zero up to time Tau, where Tau is the dosing interval (336 hours).
| day*mcg/mL | MSB0010841 30 mg | MSB0010841 60 mg | MSB0010841 120 mg | MSB0010841 240 mg |
|---|---|---|---|---|
| Area Under the Concentration-Time Curve From Time Zero up to Time Tau (AUCtau) Post First Dose of MSB0010841 | 32.4 ± 31.2 | 68.3 ± 16.4 | 114.6 ± 24.2 | 222.2 ± 19.6 |
Area under the concentration-time curve from time zero up to time Tau, where Tau is the dosing interval (336 hours).
| day*mcg/mL | MSB0010841 30 mg | MSB0010841 60 mg | MSB0010841 120 mg | MSB0010841 240 mg |
|---|---|---|---|---|
| Area Under the Concentration-Time Curve From Time Zero up to Time Tau (AUCtau) Post Third Dose of MSB0010841 | 54.2 ± 36.3 | 104.1 ± 33.9 | 203.2 ± 43.6 | 397.6 ± 27.1 |
Area under the serum concentration-time curve from time zero to infinity (AUC0-inf). AUC0-infcalculated as AUC0-t + AUCextra. AUCextra represents the extrapolated part of AUC0-inf calculated by Clast calc/λz, where Clast calc is the calculated concentration at the last sampling time point at which the measured concentration is at or above LLOQ and λz is the terminal rate constant determined from the terminal slope of the log transformed concentration curve using linear regression on terminal data points of the curve.
| day*ug/mL | MSB0010841 30 mg | MSB0010841 60 mg | MSB0010841 120 mg | MSB0010841 240 mg |
|---|---|---|---|---|
| Area Under the Concentration-time Curve From Time Zero to Infinity (AUC 0-inf) Post Third Dose of MSB0010841 | 97.6 ± 42.2 | 174.9 ± 39.9 | 392.6 ± 68.8 | 680.9 ± 32.2 |
The observed serum concentration immediately before the first dose.
| mcg/mL | MSB0010841 30 mg | MSB0010841 60 mg | MSB0010841 120 mg | MSB0010841 240 mg |
|---|---|---|---|---|
| Observed Serum Concentration Immediately Before First Dose (Cpre) of MSB0010841 | 0.01 ± 0.036 | 0.00 ± 0.000 | 0.00 ± 0.000 | 0.00 ± 0.000 |
The observed serum concentration immediately before the third dose.
| mcg/mL | MSB0010841 30 mg | MSB0010841 60 mg | MSB0010841 120 mg | MSB0010841 240 mg |
|---|---|---|---|---|
| Observed Serum Concentration Immediately Before Third Dose (Cpre) of MSB0010841 | 2.31 ± 0.59 | 4.49 ± 1.40 | 10.42 ± 4.72 | 16.17 ± 4.84 |
The observed minimum serum concentration determined directly from the serum concentration-time profile of each subject.
| mcg/mL | MSB0010841 30 mg | MSB0010841 60 mg | MSB0010841 120 mg | MSB0010841 240 mg |
|---|---|---|---|---|
| Minimum Concentration Observed (Cmin) During First Dosing Interval of MSB0010841 | 0.01 ± 0.036 | 0.00 ± 0.000 | 0.00 ± 0.000 | 0.00 ± 0.000 |
The observed minimum serum concentration determined directly from the serum concentration-time profile of each subject.
| mcg/mL | MSB0010841 30 mg | MSB0010841 60 mg | MSB0010841 120 mg | MSB0010841 240 mg |
|---|---|---|---|---|
| Minimum Concentration Observed (Cmin) During Third Dosing Interval of MSB0010841 | 2.30 ± 0.60 | 4.34 ± 1.40 | 10.03 ± 4.95 | 16.17 ± 4.84 |
| mcg/mL | MSB0010841 30 mg | MSB0010841 60 mg | MSB0010841 120 mg | MSB0010841 240 mg |
|---|---|---|---|---|
| Maximum Concentration Observed (Cmax) Post First Dose of MSB0010841 | 3.3 ± 28.4 | 7.4 ± 22.9 | 12.5 ± 25.6 | 20.8 ± 30.3 |
| mcg/mL | MSB0010841 30 mg | MSB0010841 60 mg | MSB0010841 120 mg | MSB0010841 240 mg |
|---|---|---|---|---|
| Maximum Concentration Observed (Cmax) Post Third Dose of MSB0010841 | 5.14 ± 34.5 | 11.32 ± 29.7 | 19.74 ± 31.3 | 37.93 ± 32.2 |
Cav was calculated by AUCtau/tau. Where tau is the dosing interval (336 hours).
| mcg/mL | MSB0010841 30 mg | MSB0010841 60 mg | MSB0010841 120 mg | MSB0010841 240 mg |
|---|---|---|---|---|
| Average Concentration (Cav) Post First Dose of MSB0010841 | 2.315 ± 31.2 | 4.881 ± 16.4 | 8.187 ± 24.2 | 15.868 ± 19.6 |
Cav was calculated by AUCtau/tau. Where tau is the dosing interval (336 hours).
| mcg/mL | MSB0010841 30 mg | MSB0010841 60 mg | MSB0010841 120 mg | MSB0010841 240 mg |
|---|---|---|---|---|
| Average Concentration (Cav) Post Third Dose of MSB0010841 | 3.87 ± 36.3 | 7.44 ± 33.9 | 14.51 ± 43.6 | 28.40 ± 27.1 |
MRT is the average time at which the number of absorbed molecules reside in the body, after single-dose administration, and calculated as AUMC(0-t)/AUC(0-t) where AUMC(0-t) is area under the plasma concentration-time first moment curve from time zero to time t (336 hours) and AUC(0-t) is the area under the plasma concentration-time curve from time zero to tome t (336 hours).
| day | MSB0010841 30 mg | MSB0010841 60 mg | MSB0010841 120 mg | MSB0010841 240 mg |
|---|---|---|---|---|
| Mean Residence Time (MRT0-t) Post First Dose of MSB0010841 | 6.528 ± 3.6 | 6.691 ± 8.1 | 6.638 ± 5.7 | 6.771 ± 5.3 |
MRT is the average time at which the number of absorbed molecules reside in the body, after single-dose administration, and calculated as AUMC(0-t)/AUC(0-t) where AUMC(0-t) is area under the plasma concentration-time first moment curve from time zero to time t (336 hours) and AUC(0-t) is the area under the plasma concentration-time curve from time zero to tome t (336 hours).
| day | MSB0010841 30 mg | MSB0010841 60 mg | MSB0010841 120 mg | MSB0010841 240 mg |
|---|---|---|---|---|
| Mean Residence Time (MRT0-t) Post Third Dose of MSB0010841 | 17.57 ± 11.2 | 15.68 ± 16.3 | 19.26 ± 32.0 | 16.38 ± 11.3 |
Mean residence time of drug in the body from time zero extrapolated to infinity, based on the last predicted concentration at tlast.
| day | MSB0010841 30 mg | MSB0010841 60 mg | MSB0010841 120 mg | MSB0010841 240 mg |
|---|---|---|---|---|
| Mean Residence Time of Drug in the Body From Time Zero Extrapolated to Infinity (MRT(0-inf) Post Third Dose of MSB0010841 | 17.57 ± 11.2 | 15.68 ± 16.3 | 19.26 ± 32.0 | 16.38 ± 11.3 |
| hour | MSB0010841 30 mg | MSB0010841 60 mg | MSB0010841 120 mg | MSB0010841 240 mg |
|---|---|---|---|---|
| Time to Reach Maximum Observed Concentration (Tmax) Post First Dose of MSB0010841 | 72.39 (23.9 to 97.4) | 71.68 (24.0 to 335.8) | 52.00 (32.0 to 96.2) | 72.23 (72.0 to 168.0) |
| hour | MSB0010841 30 mg | MSB0010841 60 mg | MSB0010841 120 mg | MSB0010841 240 mg |
|---|---|---|---|---|
| Time to Maximum Observed Concentration (Tmax) Post Second Dose of MSB0010841 | 84.2 (72.0 to 97.5) | 72.0 (24.1 to 96.6) | 83.4 (71.8 to 168.0) | 72.0 (24.0 to 168.0) |
| hour | MSB0010841 30 mg | MSB0010841 60 mg | MSB0010841 120 mg | MSB0010841 240 mg |
|---|---|---|---|---|
| Time to Reach Maximum Observed Concentration (Tmax) Post Third Dose of MSB0010841 | 31.5 (6.0 to 95.8) | 31.0 (12.0 to 72.4) | 72.0 (31.8 to 72.5) | 72.0 (31.1 to 168.0) |
Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life is calculated by dividing the natural logarithm to the base e (Log e) multiplied by (\*) 2/ λz, where 'λz' is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
| day | MSB0010841 30 mg | MSB0010841 60 mg | MSB0010841 120 mg | MSB0010841 240 mg |
|---|---|---|---|---|
| Apparent Terminal Half-life (t1/2) Post Third Dose of MSB0010841 | 10.63 ± 17.3 | 10.50 ± 18.9 | 12.19 ± 27.9 | 10.25 ± 13.1 |
Terminal rate constant was determined from the terminal slope of the logtransformed concentration curve using linear regression on terminal data points of the curve
| 1/hour | MSB0010841 30 mg | MSB0010841 60 mg | MSB0010841 120 mg | MSB0010841 240 mg |
|---|---|---|---|---|
| Terminal Rate Constant (λz) Post Third Dose of MSB0010841 | 0.00 ± 17.3 | 0.00 ± 18.9 | 0.00 ± 27.9 | 0.00 ± 13.1 |
Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent clearance after oral dose (CL/f) is influenced by the fraction absorbed.
| L/day | MSB0010841 30 mg | MSB0010841 60 mg | MSB0010841 120 mg | MSB0010841 240 mg |
|---|---|---|---|---|
| Apparent Clearance (CL/f) Post Third Dose of MSB0010841 | 0.55 ± 36.3 | 0.58 ± 33.9 | 0.59 ± 43.6 | 0.60 ± 27.1 |
Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution during the terminal phase, calculated as Vz = Dose/AUC0-inf multiplied by elimination rate constant \[λz\]) following first dose and Dose/(AUCtau multiplied by λz) after third dose.
| Liters | MSB0010841 30 mg | MSB0010841 60 mg | MSB0010841 120 mg | MSB0010841 240 mg |
|---|---|---|---|---|
| Apparent Volume of Distribution During Terminal Phase (Vz/f) Post Third Dose of MSB0010841 | 8.49 ± 27.0 | 8.73 ± 38.6 | 10.39 ± 21.9 | 8.92 ± 18.8 |
The peak trough fluctuation within one dosing interval, calculated as PTF (%) = (\[Cmax - Cmin\]/Cav ) multiplied by 100
| percentage fluctuation | MSB0010841 30 mg | MSB0010841 60 mg | MSB0010841 120 mg | MSB0010841 240 mg |
|---|---|---|---|---|
| Percentage Peak-Trough Fluctuation (PTF) Post First Dose of MSB0010841 | 140.28 ± 3.9 | 152.47 ± 20.4 | 144.37 ± 13.0 | 135.89 ± 12.3 |
The peak trough fluctuation within one dosing interval, calculated as PTF (%) = (\[Cmax - Cmin\]/Cav ) multiplied by 100
| percentage fluctuation | MSB0010841 30 mg | MSB0010841 60 mg | MSB0010841 120 mg | MSB0010841 240 mg |
|---|---|---|---|---|
| Percentage Peak-Trough Fluctuation (PTF) Post Third Dose of MSB0010841 | 75.26 ± 8.5 | 95.65 ± 18.9 | 71.17 ± 33.1 | 76.03 ± 28.6 |
Accumulation ratio for Cmax was calculated as Cmax, after third dose / Cmax, after first dose.
| ratio | MSB0010841 30 mg | MSB0010841 60 mg | MSB0010841 120 mg | MSB0010841 240 mg |
|---|---|---|---|---|
| Accumulation Ratio of Cmax (Racc (Cmax)) | 1.56 ± 17.9 | 1.52 ± 23.5 | 1.56 ± 34.1 | 1.81 ± 9.5 |
Accumulation ratio for AUC, calculated as area under the serum concentration-time curve within one complete dosing interval at third dose divided by area under the serum concentration-time curve within one complete dosing interval at first dose.
| ratio | MSB0010841 30 mg | MSB0010841 60 mg | MSB0010841 120 mg | MSB0010841 240 mg |
|---|---|---|---|---|
| Accumulation Ratio of AUC (Racc(AUC)) | 1.61 ± 15.9 | 1.50 ± 18.4 | 1.61 ± 27.4 | 1.83 ± 11.5 |
| mcg/mL | MSB0010841 30 mg | MSB0010841 60 mg | MSB0010841 120 mg | MSB0010841 240 mg |
|---|---|---|---|---|
| Maximum Observed Concentration (Cmax) Post Second Dose of MSB0010841 | 4.26 ± 32.7 | 9.06 ± 24.2 | 18.59 ± 23.1 | 30.98 ± 25.3 |
The observed serum concentration immediately before second dose.
| mcg/mL | MSB0010841 30 mg | MSB0010841 60 mg | MSB0010841 120 mg | MSB0010841 240 mg |
|---|---|---|---|---|
| Observed Serum Concentration Immediately Before Second Dose (Cpre) of MSB0010841 | 1.65 ± 30.2 | 3.74 ± 37.9 | 6.34 ± 38.3 | 11.44 ± 18.1 |
PASI: a physician assessed index that measured psoriasis severity and evaluated erythema, infiltration, and desquamation (scaling) on different body areas including the head, upper extremities, the trunk, and lower extremities. T Erythema, infiltration, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. These values for each anatomic region are summed to yield the PASI score. PASI score ranged from 0 to 72, with higher scores reflecting greater disease severity. PASI 50% or 75% was defined as the percentage of participants who achieved \>=50 or 75% improvement in PASI score from Baseline.
| percentage of subjects | MSB0010841 30 mg | MSB0010841 60 mg | MSB0010841 120 mg | MSB0010841 240 mg | Placebo |
|---|---|---|---|---|---|
| PASI-50 | 100 | 100 | 100 | 100 | 50 |
| PASI-75 | 88 | 100 | 100 | 100 | 0 |
PASI: a physician assessed index that measured psoriasis severity and evaluated erythema, infiltration, and desquamation (scaling) on different body areas including the head, upper extremities, the trunk, and lower extremities. T Erythema, infiltration, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. These values for each anatomic region are summed to yield the PASI score. PASI score ranged from 0 to 72, with higher scores reflecting greater disease severity. PASI 50% or 75% was defined as the percentage of subjects who achieved \>=50 or 75% improvement in PASI score from Baseline.
| units on a scale | MSB0010841 30 mg | MSB0010841 60 mg | MSB0010841 120 mg | MSB0010841 240 mg | Placebo |
|---|---|---|---|---|---|
| Baseline | 16.91 ± 5.75 | 19.76 ± 4.79 | 23.35 ± 6.60 | 18.38 ± 6.07 | 25.49 ± 5.58 |
| Change at Day 43 | -13.93 ± 4.76 | -17.99 ± 5.52 | -21.70 ± 8.52 | -16.68 ± 8.38 | -5.43 ± 7.04 |
The static Physician's Global Assessment (sPGA) scale rated the investigator's overall clinical assessment of a subjects plaque thickness, erythema, and scaling on a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (majority of plaques have severe thickness, erythema, and scale). To assign a sPGA score, the investigator examined all psoriatic lesions and assigned a severity score ranging from 0 to 5 for thickness, erythema, and scaling. Scores for thickness, erythema, and scaling are summed and the mean of these 3 scores equals the overall sPGA score. Overall sPGA score ranged from 0 to 5, where lower scores indicate clinical improvement. Percentage of subjects who achieved a sPGA rating of 0 (clear) or 1 (minimal) and had at Least 2 level reduction from Baseline score were reported.
| percentage of subjects | MSB0010841 30 mg | MSB0010841 60 mg | MSB0010841 120 mg | MSB0010841 240 mg | Placebo |
|---|---|---|---|---|---|
| Day 8 | 0 | 38 | 13 | 11 | 0 |
| Day 15 | 25 | 25 | 13 | 56 | 0 |
| Day 22 | 50 | 50 | 50 | 67 | 0 |
| Day 29 | 63 | 63 | 88 | 78 | 0 |
| Day 36 | 63 | 88 | 75 | 67 | 0 |
| Day 43 | 75 | 88 | 75 | 67 | 0 |
| Day 50 | 75 | 88 | 100 | 89 | 0 |
| Day 85 | 88 | 88 | 88 | 100 | 0 |
The BSA is the physician's evaluation for the extent of disease. The entire body area is divided into 4 districts: head, upper limbs, trunk and lower limbs to which corresponds the 10%, 20%, 30% and 40% of the entire body surface respectively. The investigator assesses the percentage of the subjects' body surface area affected by psoriasis in each district. The final affected BSA value is the sum of the percentage of each district.
| percent change | MSB0010841 30 mg | MSB0010841 60 mg | MSB0010841 120 mg | MSB0010841 240 mg | Placebo |
|---|---|---|---|---|---|
| Change at Day 8 (n=8,8,8,8,8) | 0.4 ± 1.14 | -30.0 ± 31.23 | -13.7 ± 15.13 | -12.5 ± 23.81 | 2.9 ± 23.32 |
| Change at Day 15 (n=8,8,8,8,8) | 0.4 ± 1.14 | -33.1 ± 35.97 | -20.5 ± 10.98 | -51.1 ± 43.17 | -4.2 ± 12.21 |
| Change at Day 22 (n=8,8,8,8,8) | -11.6 ± 24.90 | -40.2 ± 40.68 | -42.6 ± 27.15 | -68.5 ± 38.71 | -5.1 ± 12.69 |
| Change at Day 29 (n=8,8,8,8,8) | -22.6 ± 26.35 | -44.1 ± 42.53 | -55.9 ± 36.56 | -82.9 ± 34.46 | -0.1 ± 26.13 |
| Change at Day 36 (8,8,7,7,7) | -31.4 ± 22.96 | -52.7 ± 37.57 | -64.6 ± 37.65 | -83.5 ± 31.60 | -0.5 ± 27.92 |
| Change at Day 43 (8,8,8,9,8) | -52.6 ± 32.91 | -65.2 ± 28.61 | -75.4 ± 37.35 | -82.2 ± 36.64 | -1.5 ± 27.05 |
| Change at Day 50 (n=8,8,8,9,8) | -56.2 ± 34.71 | -69.4 ± 25.85 | -79.1 ± 32.30 | -82.2 ± 36.64 | -10.0 ± 17.87 |
| Change at Day 85 (8,8,8,9,8) | -60.4 ± 33.51 | -61.3 ± 33.89 | -82.1 ± 31.05 | -95.5 ± 11.02 | -13.0 ± 20.13 |
Psoriasis exacerbation was defined as either a worsening of 25% over the baseline value of the PASI score (PASI score at any visit \>=125% of baseline PASI).
| percentage of subjects | MSB0010841 30 mg | MSB0010841 60 mg | MSB0010841 120 mg | MSB0010841 240 mg | Placebo |
|---|---|---|---|---|---|
| Percentage of Subjects With Exacerbation of Psoriasis | 0 | 0 | 0 | 0 | 12.5 |
Collected over Baseline up to Day 85. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MSB0010841 30 mg | — | 1/8 (12.5%) | 5/8 (62.5%) |
| MSB0010841 60 mg | — | 0/8 (0%) | 5/8 (62.5%) |
| MSB0010841 120 mg | — | 0/8 (0%) | 5/8 (62.5%) |
| MSB0010841 240 mg | — | 0/9 (0%) | 6/9 (66.7%) |
| Placebo | — | 0/8 (0%) | 6/8 (75%) |
| Event | MSB0010841 30 mg | MSB0010841 60 mg | MSB0010841 120 mg | MSB0010841 240 mg | Placebo |
|---|---|---|---|---|---|
| Acute vestibular syndromeEar and labyrinth disorders | 1/8 | 0/8 | 0/8 | 0/9 | 0/8 |
| Event | MSB0010841 30 mg | MSB0010841 60 mg | MSB0010841 120 mg | MSB0010841 240 mg | Placebo |
|---|---|---|---|---|---|
| BronchitisInfections and infestations | 0/8 | 2/8 | 0/8 | 0/9 | 0/8 |
| HeadacheNervous system disorders | 0/8 | 2/8 | 0/8 | 1/9 | 0/8 |
| PruritusSkin and subcutaneous tissue disorders | 2/8 | 1/8 | 0/8 | 1/9 | 1/8 |
| PsoriasisSkin and subcutaneous tissue disorders | 0/8 | 0/8 | 0/8 | 0/9 | 2/8 |
| LeukopeniaBlood and lymphatic system disorders | 0/8 | 1/8 | 0/8 | 0/9 | 0/8 |
| Lacrimation increasedEye disorders | 0/8 | 1/8 | 0/8 | 0/9 | 0/8 |
| Hypoaesthesia oralGastrointestinal disorders | 1/8 | 0/8 | 0/8 | 0/9 | 0/8 |
| ToothacheGastrointestinal disorders | 1/8 | 0/8 | 0/8 | 0/9 | 0/8 |
| AstheniaGeneral disorders | 0/8 | 0/8 | 1/8 | 0/9 | 0/8 |
| Influenza like illnessGeneral disorders | 0/8 | 0/8 | 1/8 | 0/9 | 0/8 |
Safety analysis set included all 41 subjects who received at least 1 dose of investigational medicinal product (IMP) (MSB0010841 or placebo).
| Age, Continuous(years) | MSB0010841 30 mg | MSB0010841 60 mg | MSB0010841 120 mg | MSB0010841 240 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 48.6 ± 13.24 | 42.1 ± 19.57 | 43.8 ± 13.59 | 44.8 ± 15.65 | 46.1 ± 14.57 | 45.1 ± 14.87 |
| Gender(Participants) | MSB0010841 30 mg | MSB0010841 60 mg | MSB0010841 120 mg | MSB0010841 240 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| Female | 1 | 0 | 2 | 1 | 2 | 6 |
| Male | 7 | 8 | 6 | 8 | 6 | 35 |
The record gives a start of Aug 2014, a primary completion of Aug 2015 and a completion of Aug 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2017, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sonelokimab
Merck KGaA, Darmstadt, Germany →